Global Adalimumab Biosimilar Market By Type (Tablet, and Oral Solution), By Application (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2019-2028

“Global Adalimumab Biosimilar Market” is the title of an upcoming report offered by Market.US. This comprehensive market research report on the Adalimumab biosimilar industry contains inputs, as well as information & data from both primary and secondary sources, that have been validated and verified by target market experts. Apart from critical data and other related information, the report also includes factors that could be or are potential restraints to market growth, present & future key trends, recourses that can be leveraged for potential market expansion in untapped regions or countries, as well as factors that are presently fueling growth in the Adalimumab biosimilar market.

It also covers challenges or threats for new, as well as existing market entrants. The report presents a thorough study of revenues, key developments, strategies, historical data and information by major players that offer crucial perspectives/insights into various market scenarios. The global Adalimumab biosimilar market has been segmented on the basis of indication, distribution channel, as well as regions and countries.

The Global Adalimumab Biosimilar Market was valued at UЅD $598.3 Мn in 2020, and is projected to register а САGR of 17.6% over the next 10 years.

Request Covid - 19 Impact

Overview:

Adalimumab (Humira), is a medication that is used to treat rheumatoid arthritis, Crohn’s disease, psoriasis, uveitis, etc. A biosimilar is a biologic medical product that is highly similar, in terms of quality, efficacy and safety, to another approved biological medicine.

Dynamics:

The growing incident rates of diseases such as arthritis, cancer, irritable bowel syndrome, psoriasis, Crohn’s disease, etc., is a primary factor that is expected to continue to boost the revenue growth of the global Adalimumab biosimilar market over the next decade. The surging number of government initiatives towards the further development of medical facilities, as well as the increasing number of approvals for biosimilar products are also factors that are slated to have a positive influence on the revenue growth of this global market in the foreseeable future.

However, the high costs associated with the manufacture of biosimilars is a significant factor that may restrain the future revenue growth of the global Adalimumab biosimilar in the near future.

Nonetheless, ever since the patent for ‘Humira’ expired in 2016, there are several industry players and new market entrants vying to develop their own biosimilar products to make the most of this prospect. Factors such as the one mentioned above, is anticipated to fuel the future revenue growth of the global Adalimumab biosimilar market.

Segmentation of the global Adalimumab biosimilar market is as follows:

On the basis of indication, the rheumatoid arthritis segment accounted for the highest number of revenue shares (30.3%) of the global Adalimumab biosimilar market in 2019, owing to the increasing incidence of this disease and the effectiveness of Adalimumab biosimilars in its subsequent treatment. However, the juvenile idiopathic arthritis segment is slated to index a CAGR of 19.7% over the next 10 years.

In terms of distribution channel, the retail pharmacy segment accounted for the maximum number of revenue shares (38.8%) of the global Adalimumab biosimilar market in 2019, and is slated to register a CAGR of 25% with an attractiveness index of 5.1, over the next 10 years. The hospital pharmacy distribution channel segment is expected to for about 35% of this market’s revenue shares over the next 10 years.

Regional Segmentation and Analysis:

The markets in the Europe accounted for the highest number of revenue shares of the global Adalimumab biosimilar market in 2019, and is slated to register the highest rate of revenue growth in the foreseeable future. The markets in North America and the Asia Pacific respectively are also expected to index considerable revenue growth in the years to come.

Segmentation of the Global Adalimumab Biosimilar Market:

Segmentation by Indication:

• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Other Indications

Segmentation by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Channels

Segmentation by Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

 Key players profiled in the market report are:

• Reliance Industries Ltd.
• Pfizer Inc.
• Novartis International AD
• Fresenius SE & Co. KGaA
• Amgen Inc.
• H. Boehringer Sohn AG & Ko. KG

For the Adalimumab Biosimilar Market research study, the following years have been considered to estimate the market size: